Altimmune
ALT
119 hedge funds and large institutions have $125M invested in Altimmune in 2023 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 42 closing their positions.
104% more call options, than puts
Call options by funds: $2.04M | Put options by funds: $997K
19% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 32
10% less funds holding
Funds holding: 132 → 119 (-13)
16.53% less ownership
Funds ownership: 88.08% → 71.55% (-17%)
29% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 42
39% less capital invested
Capital invested by funds: $205M → $125M (-$80.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.45M |
| 3 |
D.E. Shaw & Co
New York
|
+$2.26M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.19M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$2.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$18.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.69M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$7.46M |
| 4 |
Goldman Sachs
New York
|
-$3.06M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.86M |
ALT Hedge Fund Activity: Q2 2023 in Review
119 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q2 2023, worth a combined $125M — down 39% from $205M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of ALT and 30 opened new positions — a net loss of 12 holders — while 32 trimmed existing stakes and 38 added.
The largest buyer was BlackRock, adding an estimated $10.2M. The largest seller was State Street, cutting an estimated $18.7M.
- 119 institutional investors held Altimmune (ALT) as of Q2 2023, down from 132 in Q1 2023.
- Funds reported $125M of Altimmune stock for Q2 2023, down 39% quarter-over-quarter.
- 30 funds opened new Altimmune positions in Q2 2023 and 42 closed out, a net change of -12 holders.
- The largest Altimmune buyer in Q2 2023 was BlackRock, an estimated $10.2M added.
- The largest Altimmune seller in Q2 2023 was State Street, an estimated $18.7M sold.
Based on aggregated 13F filings for Q2 2023.